Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy  by Mogensen, Jens et al.
F
T
F
J
J
L
H
c
p
o
(
c
p
(
g
e
p
S
M
H
t
a
Journal of the American College of Cardiology Vol. 44, No. 12, 2004
© 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00
PHypertrophic Cardiomyopathy
requency and Clinical Expression of Cardiac
roponin I Mutations in 748 Consecutive
amilies With Hypertrophic Cardiomyopathy
ens Mogensen, MD, PHD,* Ross T. Murphy, MD,* Toru Kubo, MD,*† Ajay Bahl, MD,*
ames C. Moon, MD,‡ Ib C. Klausen, MD,‡ Perry M. Elliott, MD,* William J. McKenna, MD*
ondon, United Kingdom; Kochi, Japan; and Aarhus, Denmark
OBJECTIVES The aim of this study was to evaluate the potential utility of genetic diagnosis in clinical
management of families with hypertrophic cardiomyopathy (HCM) caused by mutations in
the gene for cardiac troponin I (TNNI3).
BACKGROUND Knowledge about the clinical disease expression of sarcomeric gene mutations in HCM has
predominantly been obtained by investigations of single individuals (probands) or selected
families. To establish the role of genetic diagnosis in HCM families, systematic investigations
of probands and their relatives are needed.
METHODS Cardiac troponin I was investigated by direct sequencing and fluorescent (F)-SSCP analysis
in 748 consecutive HCM families. Relatives of HCM probands with TNNI3 mutations were
invited for cardiovascular and genetic assessment.
RESULTS The prevalence of TNNI3 mutations was 3.1%. Mutations appeared to cluster in exons 7 and
8. A total of 100 mutation carriers were identified in 23 families with 13 different mutations
(6 novel). Disease penetrance was 48%. Patients were diagnosed from the second to eighth
decade of life. The morphologic spectrum observed represented a wide range of HCM. Two
offspring of clinically unaffected mutation carriers were resuscitated from cardiac arrest, and
an additional four individuals died suddenly as their initial presentation. Six individuals
experienced other disease-related deaths.
CONCLUSIONS The clinical expression of TNNI3 mutations was very heterogeneous and varied both within
and between families with no apparent mutation- or gene-specific disease pattern. The data
suggest that disease development may be monitored by regular assessment of cardiac
symptoms and electrocardiographic abnormalities. Genetic diagnosis of TNNI3 is valuable in
identifying clinically unaffected mutation carriers at risk of disease development and facilitates
accurate management and counseling. (J Am Coll Cardiol 2004;44:2315–25) © 2004 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.05.088American College of Cardiology Foundation
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vypertrophic cardiomyopathy (HCM) is a common cardiac
ondition inherited as an autosomal dominant trait with a
revalence of approximately 1:500 (1). The diagnosis relies
n demonstration of unexplained myocardial hypertrophy
2– 4). Genetic investigations have identified disease-
See page 2326
ausing mutations in eight cardiac sarcomeric contractile
rotein genes in 50% to 60% of all patients with HCM
5–11). Sequence variations in three additional sarcomeric
enes have also been described (12–14).
Recent developments in molecular genetic methods and
quipment for mutation analysis have made it technically
ossible to provide genetic diagnosis in HCM (15). How-
From the *Department of Cardiological Sciences, St. George’s Hospital Medical
chool, London, United Kingdom; †Department of Medicine and Geriatrics, Kochi
edical School, Kochi, Japan; and ‡Department of Cardiology, Skejby University
ospital, Aarhus, Denmark. Supported by grants from the British Heart Foundation,
he Danish Medical Research Council, and the Danish Heart Foundation.f
Manuscript received January 20, 2004; revised manuscript received April 21, 2004;
ccepted May 4, 2004.ver, the use of genetic diagnosis in clinical management of
ffected HCM families is dependent on detailed informa-
ion about the genotype-phenotype correlation in relation to
ge of onset, penetrance, characteristics of disease expres-
ion, and risk of sudden death. Several studies have sug-
ested a number of possible genotype-phenotype associa-
ions, but most have been performed in small numbers of
ndividual patients (probands) or families selected for gene
dentification studies. Proband studies have provided infor-
ation about disease expression in single individuals but
ave not contained information on disease presentation in
amilies. Gene identification studies require large families
ith many affected individuals, which are rare and may not
esemble the disease expression in the much smaller families
ost frequently seen in a clinical setting (10,16–28). In this
tudy, we present a detailed analysis of the relation between
enotype and clinical phenotype in families with mutations
n the gene encoding cardiac troponin I (TNNI3) identified
y mutation analysis of 748 consecutive patients with HCM
nd their relatives. The aim was to examine the potential
alue of genetic diagnosis for management, counseling, and
ollow-up of HCM families with TNNI3 mutations.
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Troponin I Mutations in HCM December 21, 2004:2315–25ETHODS
linical investigations. The study cohort consisted of 748
onsecutive and apparently unrelated HCM probands who
ere evaluated in a dedicated cardiomyopathy clinic during
10-year period at St. George’s Hospital (London, United
ingdom). Relatives of HCM probands in whom a TNNI3
utation was identified and at risk of having inherited the
isease gene were invited for evaluation. All probands and
elatives underwent physical examination, 12-lead electro-
ardiography, 48-h Holter recording, transthoracic two-
imensional echocardiography, and Doppler studies (29).
ine cardiac magnetic resonance was performed in 30
utation carriers (30). The study was approved by the local
esearch ethics committee, and informed consent was ob-
ained from all participants.
Hypertrophic cardiomyopathy was diagnosed in probands
hen echocardiography identified unexplained left ventric-
lar (LV) hypertrophy 13 mm or LV wall thickness 2
tandard deviations for age, size, and gender or in relatives
ho fulfilled proposed diagnostic criteria within the context
f familial HCM (2,3). The pattern of hypertrophy was
lassified as asymmetrical septal hypertrophy (ASH), con-
entric, or predominant apical as previously described (31);
CM with restrictive physiology was diagnosed as reported
ecently (32). Before the present study, we were not aware
hat the patients with HCM and restrictive cardiomyopathy
RCM) in family H816 and H805 were related, and they
ere listed independently in two separate study cohorts, one
or HCM patients and one for RCM patients, respectively.
nly individual II:3 (family H816) and individual II:3
family H805) with RCM have been reported previously
32).
Supraventricular tachycardia was defined as three or more
onsecutive supraventricular premature beats at a rate of
120 beats/min. Nonsustained ventricular tachycardia was
efined as three or more consecutive ventricular ectopics at
rate of 120 beats/min lasting 30 s.
enetic investigations. Penetrance was defined as the
ercentage of clinically affected mutation carriers/(clinically
ffected  clinically unaffected mutation carriers). Probands
ere included in the calculation.
Genomic deoxyribonucleic acid for mutation analysis was
btained and protein-encoding exons (including splice sites)
Abbreviations and Acronyms
ASH  asymmetrical septal hypertrophy
ECG  electrocardiogram/electrocardiographic
F-SSCP  fluorescent SSCP
HCM  hypertrophic cardiomyopathy
LV  left ventricle/ventricular
RCM  restrictive cardiomyopathy
TNNI3  cardiac troponin If TNNI3 were amplified as previously described. Direct sequencing and fluorescent SSCP (F-SSCP) analysis was
erformed using standard protocols (15,32).
The prevalence of TNNI3 mutations was established by
irect sequencing of all eight protein-encoding exons of the
ene in 185 HCM probands. An additional 95 HCM
robands were investigated by F-SSCP analysis of all exons,
nd abnormal conformers were subjected to direct sequenc-
ng. Finally, 468 HCM probands were screened by F-SSCP
nalysis of exons 5, 7, and 8, and abnormal conformers
equenced. All mutations identified by direct sequencing
ere detectable by F-SSCP analysis implying a sensitivity of
-SSCP of 100% (15).
Five of the mutations identified were confirmed to change
estriction enzyme sites by polymerase chain reaction amplifi-
ation of the relevant exon, restriction enzyme digest, followed
y size fractionation using 3% agarose gel electrophoresis.
rg145Trp abolished an AciI site, Arg145Gly abolished an
ciI site, Ala157Val abolished a CfoI site, Arg162Gln abol-
shed a MspI site, Asp196Asn abolished a ClaI site,
er199Asn created a DdeI site, and Gly203Arg abolished an
aeIII site.
To investigate if families carrying identical mutations
ere related, haplotype analysis was performed using mic-
osatellite markers defining the TNNI3 locus. In accor-
ance with chromosome 19 sequencing data available at
CBI, TNNI3 is localized between the proximal flanking
arker D19S926 and the distally flanking markers
19S891 and D19S887; TNNI3 and D19S926 are part of
ontig NT011225, while D19S891 and D19S887 are part of
ontig NT011104 (33).
ESULTS
enetic investigations. Mutation analysis of all eight
rotein-encoding exons of TNNI3 in 280 consecutive
CM probands identified eight families with five different
utations localized in exon 7 or 8 (frequency: 2.9%) (Fig.
). The frequency of mutations identified by direct sequenc-
ng and F-SSCP was the same. Subsequent mutation
creening of 468 consecutive HCM probands was limited to
nalysis of exons 5, 7, and 8, due to the fact that no amino
cid substitutions have been identified in the remaining
xons after mutation analysis of the entire TNNI3 gene in a
otal of 1,081 HCM patients investigated in this and
revious studies (10,14,21,22,27,28,32). Mutation analysis
f exons 7 and 8 identified another eight different mutations
n 15 families (frequency: 3.2%). In total, 23 families with
3 different mutations were identified of which 6 were
ovel. All mutations were identified in patients of Cauca-
ian descent except for H305 who was Asian and H945 who
as of Arabic origin.
The mutations identified in exons 7 and 8 were all consid-
red to be disease-causing because: 1) the amino acid substi-
ution identified in the proband was present in all relatives with
he disease; 2) no sequence variations led to amino acid
ubstitutions in 150 ethnically matched control chromosomes;
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December 21, 2004:2315–25 Troponin I Mutations in HCM) identical mutations appeared in two or three separate
amilies (Arg141Gln, Arg145Trp, Ala157Val, Arg162Gln,
rg186Gln, Asp196Asn, Ser199Asn) and/or had been re-
orted previously (Arg141Gln, Arg145Gln, Ala157Val,
rg162Gln, Ser166Phe, Arg186Gln, Asp196Asn); 4) muta-
ions in this study appeared in codons previously reported to
arbor similar disease-causing amino acid substitutions
Arg145Trp, Arg162Gln, Lys183Glu, Gly203Arg); and 5) all
utations were located in functionally important and con-
erved regions of the gene (Fig. 1, Table 1) (10,14,
1,22,27,28,32).
Haplotype analysis with highly polymorphic markers
efining the locus for TNNI3 was performed in families
arrying identical mutations to investigate if the same
utation had an independent origin in separate families or
igure 1. Distribution of mutations and amino acid polymorphisms in TN
ardiomyopathy underwent mutation analysis in all protein-encoding exon
nly. Novel mutations are in italics. Exons are indicated by boxes, and i
atterns. Dotted patterns troponin T-binding domain, residue 61 to 11
lash pattern  actin-binding domain, residue 130 to 148; 173 to 181.
able 1. Conservation of Cardiac Troponin I Amino Acid Resid
Protein Encoding Exon
Amino Acid Position
Human Cardiac
Troponin I
Exon 7
141
Arg
145
Arg
157
Ala
162
Arg
amilies . . . .
81, H945 Gln . . .
215, H805, H816 . Trp . .
881 . Gln . .
167, H201, H886 . . Val .
15, H72, H772 . . . Gln
402 . . . .
12 . . . .
136, H305 . . . .
25, H655 . . . .
375, H578 . . . .
3 . . . .
909 . . . .
512 . . . .
at cardiac troponin I . . . .
ouse cardiac troponin I . . . .
hicken cardiac troponin I . . . Lys
uail cardiac troponin I . . . Lyseriod indicates amino acid identity. Protein accession numbers for rat, mouse, chicken, aas likely to have arisen from a common ancestor (founder
ffect). A unique haplotype for each of the following
utations was identified: Arg145Trp in family H816 and
805; Arg162Gln in family H15, H72, H772; Asp196Asn
n family H25, H655; Ser199Asn in family H578, H375
Fig. 2). This indicates that a common founder of the
utations in these families was likely as opposed to the
emaining families with identical mutations present on
ifferent haplotypes (Ala157Val in family H201, H886,
167; Arg186Gln in family H136, H305). No detectable
elationship was present in families sharing common hap-
otypes.
Two sequence variants identified in exon 5 led to amino
cid changes (Fig. 1). An HCM patient of Asian descent
as identified with an Arg79Cys amino acid substitution
identified in the present study. The initial 280 patients with hypertrophic
NNI3 whereas the remaining 468 were investigated in exons 5, 7, and 8
ction sites with other thin filament proteins are indicated with different
all slash pattern troponin C-binding domain, residue, 113 to 164; large
ffected by Missense Mutations
Exon 8
166
Ser
183
Lys
186
Arg
196
Asp
199
Ser
202
Glu
203
Gly
. . . . . . .
. . . . . . .
. . . . . . .
. . . . . . .
. . . . . . .
. . . . . . .
Phe . . . . . .
. Glu . . . . .
. . Gln . . . .
. . . Asn . . .
. . . . Asn . .
. . . . Gly . .
. . . . . Gly .
. . . . . . Arg
. . . . . . .
. . . . . . .
Gly . . . . . .
Gly . . . . . .NI3
s of T
ntera
2; smues And quail: NP_058840, NP_033432, P27673, and A41030, respectively (33).
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Figure 2. Pedigrees of hypertrophic cardiomyopathy (HCM) families with TNNI3 mutations. Squares  male family members; circles  female family members; symbols with slash  deceased individuals;
open symbols  unaffected individuals; solid symbols  individuals affected; question mark  unknown clinical status; plus sign  presence of mutation; minus sign  absence of mutation. No clinical
data were available in H375, II:6, but she was assumed to have HCM due to the fact that she was an obligate mutation carrier and had symptoms of disease preceding her unexplained sudden death.
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Troponin I Mutations in HCM December 21, 2004:2315–25reviously shown to be present in healthy controls of same
thnicity (10). Also, we identified a previously reported
ro82Ser amino acid substitution in an Afro-Caribbean
CM patient (14). However, we identified the same
equence variant in 3% of healthy Afro-Caribbean controls.
oth amino acid substitutions localized in exon 5 were likely
o be polymorphisms and not disease-causing mutations.
linical presentation. Genetic investigations of the 23
amilies with TNNI3 mutations identified a total of 100
utation carriers of which 48 individuals (23 probands, 25
elatives) fulfilled HCM diagnostic criteria (Table 2, Fig. 2).
total of 43 of the 48 patients with HCM had both
chocardiography recordings and electrocardiograms
ECGs) available for analysis, and 27 had hypertrophy at
nitial evaluation (Table 2). The majority of affected indi-
iduals had asymmetrical septal (n  14) or predominant
pical (n  11) hypertrophy of the LV. Three mutation
arriers (H201, II:4; H167, I:1; H136, I:2) had impaired
V systolic function (fractional shortening 25%) with an
V wall thickness ranging between 9 to 14 mm; II:4, H201,
as diagnosed at the age of 15 years after a cardiac arrest
rom which she was successfully resuscitated, whereas I:1,
167, and I:2, H136, were diagnosed due to symptoms of
eart failure and angina at the ages of 34 and 55 years,
espectively (Fig. 2, Table 2). Biopsy or postmortem mi-
roscopy of cardiac tissue from these individuals revealed
yocyte hypertrophy, interstitial fibrosis, and myofibrillar
isarray consistent with a diagnosis of “end-stage” dilated
CM.
The finding of the same mutation (Arg145Trp) in
ight affected individuals provided the opportunity to
ssess heterogeneity of disease expression within and
etween families (H215, H805, H816). In family H816,
he proband (III:2) developed severe biventricular hyper-
rophy with biatrial dilation over a 12-year period. She
ied from right- and left-sided heart failure at the age of
0. Her uncle (II:3) presented with clinical features of
CM (31). In family H805, III:4 had severe hypertrophy
30 mm), with midcavity LV obstruction at the age of 49
Fig. 3C), whereas a brother (III:6) seen at age 50 had
CG abnormalities with a normal two-dimensional
chocardiogram. Their father (II:4) was diagnosed at the
ge of 61 with ASH of 15 mm when he presented in atrial
utter, while an aunt (II:3) had previously been diag-
osed with RCM (32). In family H215, the proband
II:3) was diagnosed with ASH of 21 mm at the age of
0, whereas her father (I:1) had a normal echocardiogram
t the age of 61 but an abnormal ECG with T-wave
nversion in precordial leads (V2 through V6) and parox-
smal atrial fibrillation. He never developed morphologic
igns of HCM and died from pneumonia at the age of 74.
The heterogeneous cardiac morphology in these three
amilies was representative of the clinical findings in other
CM families with different mutations (Fig. 3). Two
atients who carried an identical mutation (Arg162Gln)
ad markedly different distribution of myocardial hypertro- dhy (Figs. 3A and 3B). Two patients had biventricular
ypertrophy with the most severe disease expression in a
atient who was homozygous for an Arg141Gln mutation
H945, II:1) (Fig. 3D). His remaining family members were
ot available for evaluation, but both parents and several of
is siblings had symptoms of cardiac disease, and one
rother had died suddenly at the age of 20. A patient with
n Arg186Gln mutation was diagnosed at the age of 29 with
evere ASH of 35 mm and developed LV wall thinning and
ilation over 13 years (Fig. 3E).
Electrocardiograms from 96 mutation carriers were avail-
ble for evaluation, of which 45 had abnormalities consis-
ent with a diagnosis of HCM in the context of familial
isease, including the presence of Q waves, ST segments, P
aves, or axis (Fig. 4). Nine mutation carriers had ECG
bnormalities with normal LV wall thickness on echocar-
iogram and no symptoms of disease (H805, III:6; H215,
:1; H201, II:2; H15, III:2, IV:1, IV:3; H136, III:2; H25,
I:3; H512, III:2) (mean age 35 years, range 14 to 72 years)
Fig. 2, Table 2). All patients with abnormal echocardiog-
aphy had ECG abnormalities and symptoms of disease
ith dyspnea and/or angina except for two patients who had
CG abnormalities, ASH of 24 mm, (H886, III:1), and
pical hypertrophy of 18 mm (H25, II:1) (age 15 and 74
ears, respectively) but no cardiac symptoms.
On Holter monitoring, 11 individuals had supraventric-
lar tachycardia (mean age 52 years, range 17 to 70 years),
hereas five individuals had episodes of nonsustained ven-
ricular tachycardia (mean age of 32 years, range 15 to 47
ears). Two individuals were successfully resuscitated after
ardiac arrest (H201, II:4 age 15; H305, II:2 age 22 years),
hereas four died suddenly (H15, IV:2 age 13; H136, II:2
ge 34; H375, II:1 age 59 and II:6 age 51 years). Five of
hese individuals fulfilled HCM diagnostic criteria on echo-
ardiography (H201, II:4; H305, II:2), postmortem exam-
nation (H15, IV:2; H136, II:2), and/or ECG recording
H375, II:1; H201, II:4; H305, II:2). No clinical data were
vailable on II:6, H375, who was an obligate mutation
arrier, but relatives reported she had symptoms of angina,
yspnea, and syncope before her otherwise unexplained
udden death. Six individuals experienced a cardiac-related
eath due to heart failure or stroke (H167, II:1; H816, III:2;
805, II:4; H12, I:1; H136, I:2; H578, I:2) (mean age 63
ears, range 40 to 72 years).
Three clinically unaffected mutation carriers (H811, II:2;
201, I:2; H305, I:1) had affected offspring of whom two
H201, II:4; H305, II:2) were successfully resuscitated from
ardiac arrest as previously mentioned.
henotypic appearance and age distribution of mutation
arriers at first clinical evaluation. The age at diagnosis of
3 probands and 25 clinically affected relatives was similar
nd evenly distributed from the second to the eighth decade
Fig. 5). A total of 52% (52 of 100) of mutation carriers had
o signs or symptoms of disease with normal ECGs and
chocardiograms at initial clinical investigation. Their age
istribution was comparable with that of clinically affected
Table 2. Phenotypic Features at First Clinical Evaluation of HCM Families With TNNI3 Mutations
Mutation Family
Individuals
Fulfilling HCM
Criteria/All
Mutation Carriers ASH
Echocardiography
(Maximal Wall-Thickness in mm)
RCM
ECG
Abnormal
Arrhythmia
SCDApical Biventricular Dilation (FS%) AF PAF NSVT
Arg141Gln H945§, H81 2/6 1 (16) 1 (34) 2 1
Arg145Trp H816, H805, H215 8/20 3 (22; 15–30) 1 (24) 2 8 4 1
Arg145Gln H811 1/5 1 (21) 1
Ala157Val H201, H886, H167 5/12 2 (24; 15–29) 2 (22; 20–24) 5 1 2 1¶
Arg162Gln H15*†, H772, H72 7/15 1 (28) 1 (19) 6 1
Ser166Phe H402 1/2 1 (19) 1
Lys183Glu H12 3/3 1 (13) 2 (22; 20–24) 3 1 1
Arg186Gln H305, H136* 5/11 2 (24; 18–30) 1 (20) 4 2#
Asp196Asn H25, H655 4/7 2 (18; 18) 1 (19) 4
Ser199Asn H578‡, H375‡ 8/13 4 (18; 16–20) 7 3 1 2
Ser199Gly H3 1/1 1 (25) 1
Glu202Gly H909 1/1 1 (19) 1
Gly203Arg H512 2/4 1 (20) 2 1
Total 23 48/100 14 (21; 13–34) 11 (21; 18–25) 2 (29; 24–34) 3 (21; 20–24) 2 45 8 3 5 6
*IV:2 (family H15) and II:2 (family H136) (Fig. 2) died suddenly at ages 13 and 32, respectively. Autopsy revealed HCM. Both had symptoms of disease but no echocardiogram or ECG was available; †II:2 (family H15) (Fig. 2)
echocardiogram not available; ‡I:2 (family H578) and II:1, II:3, II:6 (family H375) (Fig. 2); echocardiogram not available. No ECG available on II:6 (family H375). II:1 and II:6 (family H375) died suddenly at the ages of 59 and 51,
respectively; §II:2 (family H945) (Fig. 2) was homozygous for the Arg141Gln mutation; ¶II:4 (family H201) was resuscitated from cardiac arrest at the age of 15. She had an implantable cardioverter-defibrillator implanted and has been
defibrillated five times during a 20-year period; #II:2 (family H305) was resuscitated from cardiac arrest at the age of 22. She was treated with amiodarone and has not had ventricular arrhythmia for the past 12 years.
AF  atrial fibrillation; Apical  predominant apical ventricular wall hypertrophy; ASH  asymmetrical septal hypertrophy; Biventricular  hypertrophy of both left and right ventricular walls; Dilation  impaired left ventricle
function; FS%  fractional shortening; HCM  hypertrophic cardiomyopathy; NSVT  nonsustained ventricular tachycardia; PAF  paroxysmal atrial fibrillation; RCM  restrictive cardiomyopathy; SCD  sudden cardiac death.
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Troponin I Mutations in HCM December 21, 2004:2315–25igure 3. Cine cardiac magnetic resonance (CMR) images of hypertrophic cardiomyopathy (HCM) patients with TNNI3 mutations (30). A wide range
f HCM was present including: (A) asymmetrical anteroseptal hypertrophy (Arg162Gln), (B) apical hypertrophy (Arg162Gln), (C) midcavity obstruction
Arg145Trp), (D) extreme biventricular hypertrophy (Arg141Gln), (E) “end-stage dilation” (Arg186Gln), and (F) restrictive cardiomyopathy in a child six
ears of age (de novo Lys178Glu) as recently reported (did not participate in this study) (32). CMR images: (A and B) From left to right: four-chamber,
asal short-axis, and apical short-axis, all in diastole; (C to F) four-chamber systole, four-chamber diastole, short-axis diastole. (A and B) first image 
our-chamber view, diastole; second image cross-sectional view, papillary muscle level, diastole; third image cross-sectional view, apical level, diastole.
D to F) first image  four-chamber view, systole; second image  four-chamber view, diastole; third image  papillary muscle level, diastole. LA 
eft atrium; LV  left ventricle; RA  right atrium; RV  right ventricle.
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2323JACC Vol. 44, No. 12, 2004 Mogensen et al.
December 21, 2004:2315–25 Troponin I Mutations in HCMigure 4. Electrocardiograms of asymptomatic mutation carriers with normal left ventricular (LV) wall thickness on echocardiography. (A) H136, III:2 age
7 years: Q waves in III, V4 through V6; LV hypertrophy. (B) H15, III:2, age 36 years: left axis; Q waves in II, III, aVF; ST-segment abnormalities in
I, III, V2 through V6. (C) H25, II:3, age 72 years: left axis; ST-segment abnormalities in I, aVL, V5 through V6; intraventricular conduction delay, V3
hrough V4.
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Troponin I Mutations in HCM December 21, 2004:2315–25elatives and probands. The disease penetrance including
robands was 48% (48 of 100) and was incomplete in all
amilies except one (H12), where all three mutation carriers
ad HCM. A total of 33% (25 of 77) of all relatives fulfilled
CM diagnostic criteria within the context of familial
isease.
ISCUSSION
revious studies have reported TNNI3 mutations in single
atients or small numbers of HCM families with few
ffected individuals and limited clinical information
10,21,28). One study reported a heterogeneous phenotype
nd a high penetrance in several families affected by the
ame mutation (Lys183del) (22). Another classified TNNI3
utations into malignant, intermediate, or benign based on
linical information in small numbers of mutation carriers
17 with 7 different TNNI3 mutations) (27). In this study,
e demonstrate that the clinical expression of TNNI3
utations is extremely heterogeneous within and between
amilies with no apparent mutation or gene-specific disease
attern. The cardiac morphology observed in affected indi-
iduals ranged from mild ASH, apical and biventricular
ypertrophy, to “end-stage” dilated HCM, and HCM with
estrictive physiology. A similar degree of heterogeneity was
bserved in ECG abnormalities and the prevalence of
rrhythmias. Although this study was not designed to
stablish the age of disease onset, it was remarkable that
robands and affected relatives were diagnosed from the
econd to eighth decade of life. Moreover, clinically unaf-
ected mutation carriers were present at all ages and com-
rised 52% of all genotype-positive individuals. These
bservations suggest that disease development may occur
hroughout life. However, prospective follow-up studies of
linically unaffected mutation carriers is needed to deter-
ine the precise age of disease onset as well as the true
isease penetrance. The variable age of diagnosis and
npredictable disease expression of TNNI3 mutations indi-
ate that life-long follow-up of clinically unaffected muta-
ion carriers is warranted to identify and treat those at risk
igure 5. Phenotypic status and age at first clinical evaluation of all
ndividuals identified with TNNI3 mutations including probands and
linically affected and unaffected mutation carriers. The mean age at first
linical evaluation of affected individuals (probands  affected relatives)
as 39.9 years (standard deviation: 17.7) and for unaffected relatives 39.6
ears (standard deviation: 18.2). Solid bars probands; checkered bars
ffected relatives with hypertrophic cardiomyopathy; open bars  unaf-
ected relatives.f developing disease-related complications. The data sug- aest that this follow-up could be undertaken by an ECG
nd evaluation of cardiac symptoms. The recommendation
s based on the fact that all individuals who experienced
isease-related complications and those who fulfilled diag-
ostic criteria by echocardiography also had ECG abnor-
alities and cardiac symptoms. Although ECGs were
navailable in three sudden deaths, they also had a history of
ardiac symptoms, and two had hypertrophy at autopsy,
aking it likely that an ECG and symptom evaluation
ould have identified these individuals.
Other studies on probands and selected families have
uggested that mutations in different HCM genes may be
ssociated with a specific phenotype. It has been proposed
hat mutations in the gene for cardiac troponin T (TNNT2)
ay be associated with absent or mild cardiac hypertrophy
nd an adverse prognosis, whereas MYBPC3 mutations have
een associated with a more favorable outcome (17,19). The
arked clinical heterogeneity and relatively low penetrance
bserved with TNNI3 mutations illustrate that large num-
ers of consecutive genotype-positive families are needed to
stablish if specific genotype-phenotype relations are
resent in other HCM genes.
It is difficult to explain the variable disease expression
ased on existing functional studies and transgenic animal
odels expressing TNNI3 mutations, especially in families
ith identical mutations and a common ancestor present in
his study. We have recently reported a large family affected
y a TNNI3 mutation that had a more homogeneous
henotype with full disease penetrance and a high risk of
udden death (32). In contrast with most of the families in
his study who were relatively small and from predominantly
rban areas, this family originated from a rural area. It is
ikely that the genetic variation in such isolated areas is less
iverse compared with open urbanized communities, which
ould help explain the more uniform phenotype (34,35). In
ddition, environmental factors are likely to influence the
henotypic expression of HCM, making it difficult to
redict disease development and prognosis of individual
atients with diverse genetic backgrounds.
The results of mutation analysis of all protein-encoding
xons of TNNI3 in 1,081 HCM patients in this and
revious studies have not revealed any disease-causing
utations outside exons 7 and 8 (10,14,27,28). Thus, the
robability of identifying a mutation outside these exons
ould be 1:1,081 (0.09%), and, therefore, it seems
easonable to limit mutation analysis of TNNI3 to exons 7
nd 8. In addition, F-SSCP analysis was shown to be an
ppropriate method for mutation screening with the advan-
age of being cheaper, faster, and more suitable for high-
hroughput analysis than direct sequencing. Knowledge of
he genetic status enhances the ability to provide accurate
ounseling of clinically unaffected relatives. Individuals who
re shown to carry the mutation can be informed that
isease penetrance is 48%, that age of diagnosis is variable,
nd that clinically unaffected carriers are at risk of having
ffected offspring who may experience disease-related com-
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December 21, 2004:2315–25 Troponin I Mutations in HCMlications. It is important to emphasize that individuals
ithout the mutation have no risk of developing or passing
he disease on to their offspring. Thus, genetic diagnosis
dentifies relatives who require follow-up and enables ter-
ination of cardiac evaluation in individuals without the
utation, which is of great relief. This also facilitates
ost-effective use of resources for clinical screening.
In summary, the severity of disease expression in HCM
robands with TNNI3 mutations does not predict the
everity or timing of disease development in genotype-
ositive offspring, siblings, and other relatives. The previous
oncept that knowledge of specific mutations would provide
ufficient prognostic information to determine prophylactic
reatment for sudden death was not substantiated. However,
he fact that clinically unaffected mutation carriers may have
ffspring who present with sudden death and the overall
npredictability in disease development and complications
uggest that genetic diagnosis is important, particularly in
naffected offspring. This will define the relevant subgroup
f individuals who require clinical follow-up by ECG and
onitoring of cardiac symptoms. Implementation of genetic
iagnosis of TNNI3 is technically feasible, and the data
upport a potentially clinical utility in HCM.
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